Back to results
US 10,849,969 B2Granted
Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity
AssigneeInstitut Pasteur
InventorsSylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet
Life of this patent
Estimating the term…
Abstract
A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
Claims14
A recombinant attenuated Mopeia virus (MOPV) comprising a heterologous nucleic acid encoding a non-MOPV arenavirus glycoprotein and a nucleic acid encoding an MOPV nucleoprotein having attenuated exonuclease activity,
- wherein the attenuated MOVP nucleoprotein comprises the amino acid substitutions D390X and G393X, wherein said numbering is based upon the isolate AN21366, and
- wherein replication of the recombinant attenuated MOPV in dendritic cells (DC) and/or in macrophages (MP) is reduced by at least 10% compared to replication of recombinant wild type (rec-MOPV) or wild type MOPV (nat-MOPV) in the same cell type.
Dependencies are inferred from the claim text.